Supersymmetric AdS vacua and separation of scales

The moduli space of the supersymmetric massive IIA AdS4xS2(B4) vacua, where S2(B4) is a two-sphere bundle over a four-dimensional Kaehler-Einstein base B4, includes three independent parameters which can be thought of as corresponding to the sizes of AdS4, B4 and the S2 fiber. It might therefore be expected that these vacua do not suffer from the absence of scale separation. We show that the independence of the geometric moduli survives flux quantization. However, we uncover an attractor behavior whereby all sizes flow to equality in some neighborhood of spacetime independently of the initial conditions set by the parameters of the solution. This is further confirmed by the study of the ratio of internal to external scalar curvatures. We also show that the asymptotic Kaluza-Klein spectrum of a ten-dimensional massive scalar is governed by a scale of the order of the AdS4 radius. Furthermore we point out that the curvature ratio in supersymmetric IIA AdS4 vacua with rigid SU(3) structure is of order one, indicating the absence of scale separation in this large class of vacua.Comment: 21 pages, 2 figures; v2 typos correcte

M-Theory on (K3 X S^1)/Z_2

We analyze $M$-theory compactified on $(K3\times S^1)/Z_2$ where the $Z_2$ changes the sign of the three form gauge field, acts on $S^1$ as a parity transformation and on K3 as an involution with eight fixed points preserving SU(2) holonomy. At a generic point in the moduli space the resulting theory has as its low energy limit N=1 supergravity theory in six dimensions with eight vector, nine tensor and twenty hypermultiplets. The gauge symmetry can be enhanced (e.g. to $E_8$) at special points in the moduli space. At other special points in the moduli space tensionless strings appear in the theory.Comment: LaTeX file, 11 page

Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance

Nancy El-Helou, Amal Al-Hajje, Rola Ajrouche, Sanaa Awada, Samar Rachidi, Salam Zein, Pascale SalamehClinical and Epidemiological Research Laboratory, Faculty of Pharmacy, Lebanese University, Beirut, LebanonBackground: Adverse drug events (ADE) occur frequently during treatment with vitamin K antagonists (AVK) and contribute to increase hemorrhagic risks.Methods: A retrospective study was conducted over a period of 2 years. Patients treated with AVK and admitted to the emergency room of a tertiary care hospital in Beirut were included. The aim of the study was to identify ADE characterized by a high international normalized ratio (INR) and to determine the predictive factors responsible for these events. Statistical analysis was performed with the SPSS statistical package.Results: We included 148 patients. Sixty-seven patients (47.3%) with an INR above the therapeutic range were identified as cases. The control group consisted of 81 patients (54.7%) with an INR within the therapeutic range. Hemorrhagic complications were observed in 53.7% of cases versus 6.2% of controls (P < 0.0001). No significant difference was noticed between cases and controls regarding the indication and the dose of AVK. Patients aged over 75 years were more likely to present an INR above the therapeutic range (58.2%, P = 0.049). Recent infection was present in 40.3% of cases versus 6.2% of controls (P < 0.0001) and hypoalbuminemia in 37.3% of cases versus 6.1% of controls (P < 0.0001). Treatment with antibiotics, amiodarone, and anti-inflammatory drugs were also factors of imbalance (P < 0.0001).Conclusion: Many factors may be associated with ADE related to AVK. Monitoring of INR and its stabilization in the therapeutic range are important for preventing these events.Keywords: adverse drug events, vitamin K antagonists, bleeding risks, therapeutic imbalanc

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor molecule DNAX-activating protein of 10 kDa (DAP10) to provide co-stimulatory signal upon ligand binding. NKG2D binds eight different ligands expressed on the cell surface of many tumour cells and which are normally absent on non-neoplastic cells. In preclinical studies, NKR-2 demonstrated long-term antitumour activity towards a breadth of tumour indications, with maximum efficacy observed after multiple NKR-2 administrations. Importantly, NKR-2 targeted tumour cells and tumour neovasculature and the local tumour immunosuppressive microenvironment and this mechanism of action of NKR-2 was established in the absence of preconditioning. Methods and analysis: This open-label phase I study will assess the safety and clinical activity of NKR-2 treatment administered three times, with a 2-week interval between each administration in different tumour types. The study will contain two consecutive segments: a dose escalation phase followed by an expansion phase. The dose escalation study involves two arms, one in solid tumours (five specific indications) and one in haematological tumours (two specific indications) and will include three dose levels in each arm: 3x10(8), 1x10(9) and 3x10(9) NKR-2 per injection. On the identification of the recommended dose in the first segment, based on dose-limiting toxicity occurrences, the study will expand to seven different cohorts examining the seven different tumour types separately. Clinical responses will be determined according to standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria for solid tumours or international working group response criteria in haematological tumours. Ethics approval and dissemination: Ethical approval has been obtained at all sites. Written informed consent will be taken from all participants. The results of this study will be disseminated through presentation at international scientific conferences and reported in peer-reviewed scientific journals

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Purpose: This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC). Patients and Methods: Women with MBC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced/metastatic disease. Stratification factors were human epidermal growth factor receptor-2 (HER2) status and geographic region. Coprimary end points were overall survival (OS) and progression-free survival (PFS). Results: Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056). Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30). Objective response rates were 11.0% for eribulin and 11.5% for capecitabine. Global health status and overall quality-of-life scores over time were similar in the treatment arms. Both treatments had manageable safety profiles consistent with their known adverse effects; most adverse events were grade 1 or 2. Conclusion: In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS

Higher Order Integrability in Generalized Holonomy

Supersymmetric backgrounds in M-theory often involve four-form flux in addition to pure geometry. In such cases, the classification of supersymmetric vacua involves the notion of generalized holonomy taking values in SL(32,R), the Clifford group for eleven-dimensional spinors. Although previous investigations of generalized holonomy have focused on the curvature \Rm_{MN}(\Omega) of the generalized SL(32,R) connection \Omega_M, we demonstrate that this local information is incomplete, and that satisfying the higher order integrability conditions is an essential feature of generalized holonomy. We also show that, while this result differs from the case of ordinary Riemannian holonomy, it is nevertheless compatible with the Ambrose-Singer holonomy theorem.Comment: 19 pages, Late

Subleading Corrections and Central Charges in the AdS/CFT Correspondence

We explore subleading contributions to the two basic central charges c and a of four-dimensional conformal field theories in the AdS/CFT scheme. In particular we probe subleading corrections to the difference c-a from the string-theory side. In the N=4 CFT, c-a vanish identically consistently with the string-theory expectations. However, for N=1 and N=2 CFTs, the U_R(1) anomaly, which is proportional to c-a, is subleading in the large N limit for theories in the AdS/CFT context and one expects string one-loop R^2 and B \wedge R \wedge R terms in the low energy effective action. We identify these terms as coming from the R^4 terms. Similar considerations apply to the U_R(1)^3 anomaly which is, however, subleading only for N=2 theories. As a result, a string one-loop term B \wedge F \wedge F should exist in the low energy effective action of the N=4 five-dimensional supergravity. The U_R(1)^3 term is leading for the N=1 CFT and it is indeed present in the N=2 five-dimensional supergravity.Comment: 15 page

Holography in asymptotically flat space-times and the BMS group

In a previous paper (hep-th/0306142) we have started to explore the holographic principle in the case of asymptotically flat space-times and analyzed in particular different aspects of the Bondi-Metzner-Sachs (BMS) group, namely the asymptotic symmetry group of any asymptotically flat space-time. We continue this investigation in this paper. Having in mind a S-matrix approach with future and past null infinity playing the role of holographic screens on which the BMS group acts, we connect the IR sectors of the gravitational field with the representation theory of the BMS group. We analyze the (complicated) mapping between bulk and boundary symmetries pointing out differences with respect to the AdS/CFT set up. Finally we construct a BMS phase space and a free hamiltonian for fields transforming w.r.t BMS representations. The last step is supposed to be an explorative investigation of the boundary data living on the degenerate null manifold at infinity.Comment: 31 pages, several changes in section 3 and 7 and references update

The GS String Action on AdS(3)xS(3) with Ramond-Ramond Charge

We derive the classical kappa-symmetric Type IIB string action on AdS(3) x S(3) by employing the SU(1,1|2)^2 algebra. We then gauge fix kappa-symmetry in the background adapted Killing spinor gauge and present the action in a very simple form.Comment: 19 pages, LaTe

Searching for a Connection Between Matroid Theory and String Theory

We make a number of observations about matter-ghost string phase, which may eventually lead to a formal connection between matroid theory and string theory. In particular, in order to take advantage of the already established connection between matroid theory and Chern-Simons theory, we propose a generalization of string theory in terms of some kind of Kahler metric. We show that this generalization is closely related to the Kahler-Chern-Simons action due to Nair and Schiff. In addition, we discuss matroid/string connection via matroid bundles and a Schild type action, and we add new information about the relationship between matroid theory, D=11 supergravity and Chern-Simons formalism.Comment: 28 pages, LaTex, section 6 and references adde